- Home
- MNTK vs AUTL Comparison
MNTK vs AUTL Comparison
Compare MNTK & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNTK | AUTL |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.6M | 335.4M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MNTK | AUTL |
|---|---|---|
| Price | $0.96 | $1.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $1.55 | ★ $8.36 |
| AVG Volume (30 Days) | 631.5K | ★ 2.5M |
| Earning Date | 11-16-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $176,382,000.00 | $10,120,000.00 |
| Revenue This Year | $20.57 | $101.75 |
| Revenue Next Year | $16.34 | $29.27 |
| P/E Ratio | $146.00 | ★ N/A |
| Revenue Growth | 0.37 | ★ 496.00 |
| 52 Week Low | $0.95 | $1.12 |
| 52 Week High | $3.28 | $2.58 |
Technical Indicators
Market Signals| Indicator | MNTK | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 28.76 | 24.83 |
| Support Level | N/A | N/A |
| Resistance Level | $1.72 | $1.71 |
| Average True Range (ATR) | 0.28 | 0.11 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 0.24 | 9.43 |
Price Performance
Historical ComparisonAbout MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.